Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aguracingene cadoparvovec - Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Aguracingene cadoparvovec - Johnson & Johnson Innovative Medicine

Alternative Names: A-003 - MeiraGTx; AAV-CNGA3; AAV2/8-hG1.7p.coCNGA3; CNGA3-gene-therapy-AGTC; Recombinant-adeno-associated-virus-vector-expressing-GNGA

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCL Business
  • Developer MeiraGTx
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colour vision defects

Most Recent Events

  • 31 Dec 2023 MeiraGTx has patent pending for compositions of matter and methods of use relating to achromatopsia program and the AAV-CNGA3 product candidate in USA, Indonesia and Japan before December 2023
  • 31 Dec 2023 MeiraGTx has patent pending for compositions of matter and methods of use relating to achromatopsia program and the AAV-CNGA3 product candidate in USA, Africa, Australia, Brazil, Canada, China, Egypt, Eurasia, Europe, Hong Kong, India, Israel, Republic of Korea, Malaysia, Mexico, New Zealand, Philippines, Singapore, South Africa and Vietnam before December 2023
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top